Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

Medulloblastoma is the most common malignant brain tumor in children. Aberrant activation of the hedgehog signaling pathway is strongly implicated in the development of some cases of medulloblastoma. A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms. Molecular analyses of tumor specimens obtained before treatment suggested that there was activation of the hedgehog pathway, with loss of heterozygosity and somatic mutation of the gene encoding patched homologue 1 (PTCH1), a key negative regulator of hedgehog signaling.

[1]  Raoul Tibes,et al.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.

[2]  C. Rudin,et al.  355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449 , 2008 .

[3]  C. Eberhart,et al.  Medulloblastoma stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Curran,et al.  Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. , 2008, Cancer cell.

[5]  D. Ellison,et al.  The origins of medulloblastoma subtypes. , 2008, Annual review of pathology.

[6]  T. MacDonald,et al.  Medulloblastoma in childhood: new biological advances , 2007, The Lancet Neurology.

[7]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[8]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[9]  D. Haber,et al.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Kantarjian,et al.  New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance , 2006, Annals of Internal Medicine.

[11]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[12]  P. Ingham,et al.  Orchestrating ontogenesis: variations on a theme by sonic hedgehog , 2006, Nature Reviews Genetics.

[13]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Kessler,et al.  Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma , 2005, Development.

[15]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Helen Baines,et al.  Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. , 2004, Cancer cell.

[17]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Heather L. Miller,et al.  A molecular fingerprint for medulloblastoma. , 2003, Cancer research.

[19]  James M. Olson,et al.  Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade , 2002, Science.

[20]  D. Rowitch,et al.  Sonic hedgehog Promotes G1 Cyclin Expression and Sustained Cell Cycle Progression in Mammalian Neuronal Precursors , 2000, Molecular and Cellular Biology.

[21]  L. Rorke,et al.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Scott,et al.  Altered neural cell fates and medulloblastoma in mouse patched mutants. , 1997, Science.

[23]  J. Miro,et al.  PATIENTS AND METHODS , 1978 .

[24]  M. Scott,et al.  Control of Neuronal Precursor Proliferation in the Cerebellum by Sonic Hedgehog , 1999, Neuron.